Released Mar 12, 2020, after the close
10-K filed Mar 13, 2020, 73 days after period end · 0001390478-20-000007
Q4 2019 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$7.42M-$7.42M derivedN/M vs Q4 2018N/M vs Q3 2019
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Cash Flowderived-$4,176,000N/M
What the release said
The release
Same quarter
| Metric | Q4 2019dderived from reported figures | Q4 2018dderived from reported figures | Q4 2017dderived from reported figures | Q4 2016dderived from reported figures |
|---|---|---|---|---|
| Net Income | -$7.42M | -$13.32M | -$8.79M | $352.00K |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR